Collaborations & Alliances

ISIS Pharmaceuticals Earns $5 Million from GSK

Relates to initiation of phase 1 study of ISIS-GSK4-L Rx

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isis Pharmaceuticals Inc. has earned a $5 million milestone payment from GSK related to the initiation of a Phase 1 study of ISIS-GSK4-LRx. ISIS-GSK4-LRx is one of five drugs in development with GSK and is designed to treat patients with an undisclosed ocular disorder. GSK and Isis have established an alliance focused on leveraging antisense technology to develop drugs to treat rare and infectious diseases. This alliance provides GSK with access to Isis’ expertise in RNA-targeted drug dis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters